Synonyms: Ebglyss® | MILR1444A | RG3637 | TNX-650
lebrikizumab is an approved drug (EMA (2023))
Compound class:
Antibody
Comment: Lebrikizumab is a an anti-IL-13 monoclonal antibody.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. |
Classification | |
Compound class | Antibody |
Approved drug? | Yes (EMA (2023)) |
International Nonproprietary Names | |
INN number | INN |
9165 | lebrikizumab |
Synonyms |
Ebglyss® | MILR1444A | RG3637 | TNX-650 |
Database Links | |
Specialist databases | |
IMGT/mAb-DB | 325 |
Other databases | |
GtoPdb PubChem SID | 223366019 |
Search PubMed clinical trials | lebrikizumab |
Search PubMed titles | lebrikizumab |
Search PubMed titles/abstracts | lebrikizumab |
Wikipedia | Lebrikizumab |